Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by George Gao and Wenjie Tan.
George Gao
Connection Strength
0.508
Wenjie Tan
  1. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020 09 04; 11(1):4417.
    View in: PubMed
    Score: 0.225
  2. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduct Target Ther. 2021 02 04; 6(1):51.
    View in: PubMed
    Score: 0.058
  3. Immune suppression in the early stage of COVID-19 disease. Nat Commun. 2020 11 17; 11(1):5859.
    View in: PubMed
    Score: 0.057
  4. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 01; 21(1):39-51.
    View in: PubMed
    Score: 0.057
  5. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020 08 06; 182(3):713-721.e9.
    View in: PubMed
    Score: 0.055
  6. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020 06 12; 368(6496):1274-1278.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.